What To Know
- Erickson holds a Master of Science Degree in Management, Bachelor of Science degrees in both Chemistry and Biology, and has completed graduate studies in Biochemistry, Toxicology and Endocrinology.
- “His extensive and demonstrable record of accomplishment in helping to commercialize new diagnostics technologies in particular will be a great asset for RNA Disease Diagnostics going forward.
RNA Disease Diagnostics, Inc., a company developing a best-in-class molecular diagnostics platform for infectious disease detection, announced today the appointment of John W. Erickson, Jr. to the newly created position of President.
John W. Erickson will lead day-to-day operations, reporting directly to RNA Disease Diagnostics co-founder and Executive Chairman, Allan Oberman.
In an executive management career spanning more than three decades, Mr. Erickson has worked with healthcare, life science, and clinical diagnostics businesses ranging from venture capital-backed start-ups to Fortune 50 companies, building out global commercial capabilities, leading marketing and sales teams, delivering operational excellence and profitable growth, while cultivating strong thought leader relationships across multiple specialties.
Erickson joins RNA Disease Diagnosticsfrom his management and strategy consulting firm, Erickson Healthcare Consulting, which he founded in 2017. Previously, he held C-suite and senior executive leadership positions with RapidBio Systems, Johnson & Johnson (LifeScan), Abbott Laboratories, ITC-Nexus Dx, and Bio-Rad Laboratories. Notably, in those roles, Mr. Erickson played a key role in the development and commercialization of over 36 products, which have generated cumulative sales in excess of $4 billion. Mr. Erickson holds a Master of Science Degree in Management, Bachelor of Science degrees in both Chemistry and Biology, and has completed graduate studies in Biochemistry, Toxicology and Endocrinology.
“I am very pleased to have recruited an executive of John’s caliber to this key position,” said Mr. Oberman. “His extensive and demonstrable record of accomplishment in helping to commercialize new diagnostics technologies in particular will be a great asset for RNA Disease Diagnostics going forward. John is exceptionally qualified to help us maximize the development and commercialization of our Antisense RNA diagnostic platform across multiple diseases.”